Versant Ventures
Investor profile
Investment firm
Deals
8
distinct rounds
Companies
6
backed
Active span
2014–2024
11 yrs
Total round €
€385M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- LSP3
- Abingworth LLP2
- SR One2
- 5AM Ventures1
- Andera Partners1
- Bayer Global Investments1
- CaaS Capital Management1
- Casdin Capital1
- Celgene1
- Dawn Biopharma1
- Epidarex Capital1
- Export and Investment Fund of Denmark (EIFO)1
- Fidelity Management & Research Company LLC1
- Forbion1
- GlaxoSmithKline1
- IP Group1
- Longview Ventures1
- New Enterprise Associates1
- Novartis Venture Fund1
- Novo Holdings1
- Panakès Partners1
- Pictet1
- Qatar Investment Authority1
- RA Capital Management1
- Sixty Degree Capital1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| T-knife | Germany | 1 | €94M |
| CRISPR Therapeutics | Switzerland | 2 | €81M |
| Antag Therapeutics | Denmark | 1 | €80M |
| Nouscom | Switzerland | 2 | €54M |
| Cimeio Therapeutics | Switzerland | 1 | €46M |
| Enterprise Therapeutics | UK | 1 | €30M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| T-knife | Series B | €94M | 2021-08 |
| Antag Therapeutics | Series A | €80M | 2024-12 |
| CRISPR Therapeutics | Series B | €58M | 2015-03 |
| Cimeio Therapeutics | Series A | €46M | 2022-04 |
| Nouscom | Series B | €42M | 2017-11 |
| Enterprise Therapeutics | Series B | €30M | 2024-01 |
| CRISPR Therapeutics | Series A | €23M | 2014-03 |
| Nouscom | Series A | €12M | 2016-04 |